SB 248 amends Utah’s controlled substances laws, focusing on the state’s limited behavioral-health exception for psilocybin and methylenedioxymethamphetamine (MDMA). The bill revises who may operate a treatment program under that exception, replacing the prior reference to certain healthcare systems with narrower categories of providers: a cancer treatment center with a palliative care provider, or a licensed psychiatrist with experience administering a drug in a legal clinical trial. It also changes the supervision standard from direct to indirect supervision, keeps the treatment limited to adults 18 and older, and extends the deadline for the required legislative report from July 1, 2026 to July 1, 2027.
The bill also adds an automatic rescheduling provision for crystalline polymorph psilocybin: if the federal government places that specific composition into a schedule other than Schedule I, Utah will deem it scheduled in the same federal schedule. In addition, it extends the repeal date for the behavioral-health treatment section from July 1, 2027 to July 1, 2029, allowing the program to continue longer before sunset. The bill makes no appropriation and takes effect May 7, 2025.
Impact
SB 248 amends Utah Code Sections 58-37-3.5, 58-37-4, and 63I-1-258. Its main legal effect is to narrow and clarify the entities that may run a psilocybin/MDMA behavioral health treatment program, adjust the supervision requirement, and preserve immunity for compliant use, possession, distribution, administration, or supervision under that section. It also creates a federal-conformity mechanism for crystalline polymorph psilocybin scheduling and extends the sunset date for the section, thereby prolonging the state’s controlled-substances pilot framework for these substances.
Sentiment
The available voting history suggests strong committee support: the Senate committee reported both a substitute recommendation and a favorable recommendation by 5-0 votes. No committee transcript excerpts were provided, so there is no recorded debate to indicate significant opposition in the materials supplied. Overall, the bill appears to have been received positively at the committee stage.
Contention
The likely points of contention are the bill’s continued carve-out for psilocybin and MDMA-related treatment, the narrowing of eligible providers, and the shift from direct to indirect supervision. Supporters would likely view the bill as a cautious way to continue research-oriented behavioral health treatment while keeping adult-only limits and reporting requirements. Potential critics could object either to expanding access to controlled substances in a clinical setting or, conversely, to the bill’s tighter provider definitions and continued restrictions, depending on their view of the underlying program.